A phase IIa, open-label, single-arm, two stage, multi-centre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of repeated subcutaneous administration of BIM23B065 in subjects with acromegaly
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs BIM 23B065 (Primary)
- Indications Acromegaly
- Focus Pharmacodynamics
- Sponsors Ipsen
- 25 Jul 2017 Status changed from recruiting to discontinued as per sponsor decision. No new safety signal or serious adverse event has been observed.
- 23 Jun 2017 This trial has been discontinued in Hungary.
- 17 Jun 2017 This trial has been discontinued in Bulgaria.